Molecules that regulate lymphocyte homeostasis, proliferation, and survival operate in concert to enable robust adaptive immune responses to foreign antigens (Ags). For the B cell lineage, the optimal outcome of these processes is a diverse antibody (Ab) repertoire purged of pathological (self-reactive) B cells. The elimination of pathological B cells occurs either through clonal deletion or receptor editing during B lymphopoiesis in the bone marrow, or in the periphery through the induction of anergy (Goodnow et al., 1988; Nemazee and Bürki, 1989; Gay et al., 1993; Tiegs et al., 1993) . Anergic B cells primarily inhabit the spleen, are short-lived, and undergo activation-induced cell death (AICD) in response to B cell Ag receptor (BCR) stimulation (Goodnow et al., 1995; Shlomchik, 2008) .
BCR ligation by agonistic anti-IgM Abs induces 30-50% of spleen B cells from WT mice to blast and undergo proliferation ex vivo (DeFranco et al., 1982) . However, the threshold for B cell AICD can be influenced by genetically altering the stimulatory and inhibitory pathways that regulate BCR-induced activation (Inaoki et al., 1997) . The B cell-restricted surface protein CD22 is generally considered to negatively regulate BCR signaling by recruiting potent intracellular phosphatases after BCR ligation (Doody et al., 1995; O'Keefe et al., 1996; Otipoby et al., 1996; Sato et al., 1996; Nitschke et al., 1997; Tedder et al., 1997; Poe et al., 2000) , and CD22 / mice produce augmented levels of isotype-switched auto-Abs against DNA and some protein Ags (O'Keefe et al., 1999; Poe et al., 2011) . Nevertheless, B cells from inbred CD22 / mice with a B6/129 genetic background (CD22 / [inbr] ) are phenotypically and functionally normal ex vivo (Poe et al., 2004) . In contrast, spleen B cells from C57BL/6 (B6) mice genetically deficient in CD22 (CD22 /[B6] ) undergo AICD after BCR stimulation (Poe et al., 2004) , which is likely to be a result of their inability to induce c-Myc transcription factor expression that balances B cell proliferation versus AICD (Donjerković and Scott, 2000; Poe et al., 2004) . These striking phenotypic differences in B cells between mouse lines with a common deletion of Cd22 indicate that important B cell signaling events that promote AICD are influenced differently by the B6 and 129 genetic backgrounds. These two CD22 / mouse lines were therefore used to identify genetic and molecular factors regulating B cell AICD.
In these studies, a forward genetic screen was used to identify an evolutionarily conserved single-stranded RNA (ssRNA) binding protein, EndoU, as a novel regulator of AICD in CD22 /[B6] mice. EndoU was also overexpressed by anergic peripheral B cells from double-transgenic mice expressing BCRs specific for hen egg lysozyme (HEL) along with soluble HEL (sHEL) as the cognate auto-Ag (Ig Tg sHEL mice; Goodnow et al., 1989; Hippen et al., 2000; Shlomchik, 2008) . EndoU deficiency in Ig Tg sHEL mice also reversed AICD ex vivo and led to augmented anti-HEL auto-Ab responses in vivo. Thus, EndoU defines a new posttranscriptional regulatory pathway that controls B cell AICD, particularly in response to auto-Ag. Values represent mean (±SEM) cpm for triplicate wells from one of three independent experiments producing similar results. **, P < 0.01, Student's t test. (C) Representative CD5 immunofluorescence staining of freshly isolated B220 + splenocytes from ≥5 mice/group of the indicated genotypes. Background staining using an isotype-matched control mAb is shown (Neg Ctl). (D) Spleen B cells from WT [B6] or CD22 /[B6] mice were cultured with F(ab') 2 anti-IgM Abs for 18 h. [ 32 P]-radiolabeled cDNA was generated from total RNA, followed by hybridization to GEArray signaling pathway gene arrays. (Fig. 2 F) , including refined border regions for mice #14 and #28. Mice having apparently discordant levels ( Fig. 2 B , bottom dot plots), which correlated directly with increased or normal CD5 expression, respectively. These results confirmed the existence of a genetic modifier locus/ loci that regulates BCR-induced AICD and CD5 expression.
A genetic locus regulates AICD of B cells from CD22 /[B6] mice
Segregation of the B cell survival versus AICD phenotypes in CD22 /[N1] mice indicated that the genomes of the parental CD22 / mouse lines were stable and amenable to genetic analyses. Therefore, a forward genetic linkage analysis was used to identify the gene locus/loci responsible for CD22 /[B6] B cell AICD. Genome-wide genotyping of 250 informative single nucleotide polymorphisms (SNPs) between the B6 and 129 mouse strains used genomic DNA from 44 CD22 /[N1] mice; 22 mice had viable B cells after BCR ligation, whereas 22 mice had B cells that underwent AICD (Fig. 2 C) . Quantitative trait loci (QTL) mapping regression analysis revealed a single locus with high logarithm of odds (LOD) scores (P < 10 6 ) on the distal end of chromosome (Chr) 15 (Fig. 2 D) , (D) Purified spleen B cells from the indicated mice were cultured alone or with F(ab') 2 anti-IgM Abs for 18 h. Total cellular proteins were separated by SDS-PAGE, followed by transfer to nitrocellulose membranes and Western blot analysis using polyclonal anti-EndoU Ab as described in C. Bar graphs indicate mean EndoU band densities from three each Ig Tg and Ig Tg sHEL mice as assessed in two independent experiments producing similar results. **, P < 0.01, Student's t test. (E) [ 32 P]-labeled ssRNA substrates described for XendoU (Laneve et al., 2008) were incubated with recombinant EndoU protein in the presence or absence of Mn 2+ or EDTA as indicated. (Fig. 3 A) . B cells from WT [B6] mice expressed EndoU at lower levels than B cells from WT 129 (WT [129] ) mice before and after BCR ligation ( Mammalian EndoU is a uridine-directed ssRNA binding protein EndoU function in mammals is unknown, although EndoU transcripts are abundant in glucocorticoid-sensitive thymocytes undergoing apoptosis (Baughman et al., 1992) . Highly conserved EndoU orthologs are found in many advanced and primitive species (see Fig. 8 A; Renzi et al., 2006) , but EndoU paralogs derived from ancestral gene duplications do not exist in mice. The Xenopus ortholog of EndoU, XendoU, has been defined as an endonuclease targeting ssRNA molecules harboring polyuridine (poly(U)) regions (Renzi et al., 2006) . Because EndoU substrates have not been defined in other species and EndoU-related molecules that could share redundant activities are not found in mice, the ability of EndoU to bind and/or process XendoU ssRNA substrates was examined. Recombinant EndoU protein specifically bound poly(U) ssRNAs, but not ssRNA species lacking these sites (Fig. 3 E) . However, EndoU did not cleave these poly(U) ssRNAs, even c-Myc expression in CD22 /[B6] B cells after BCR ligation because proliferating cell nuclear Ag (PCNA) was expressed at normal levels ( Fig. 5 E) , as reported for other molecules critical for cell cycle progression (Poe et al., 2004 (Fig. 5 F) that results from enhanced BCR tonic signals in the absence of CD22 negative regulation (Doody et al., 1995; O'Keefe et al., 1996; Otipoby et al., 1996; Sato et al., 1996; Nitschke et al., 1997; Tedder et al., 1997) . Otherwise, the modest reductions in surface IgD and CD21 expression that characterize CD22 /[B6] B cells (Poe et al., 2004) were normalized in EndoU / CD22 /[B6] B cells (Fig. 5 F) . Enhanced heat stable Ag (HSA/CD24) expression is commonly used as a marker for immature/ transitional B cells, but as with CD5, enhanced HSA expression is also characteristic of chronically stimulated or anergic B cells (Noorchashm et al., 1999) . Regardless, the characteristic CD5 high HSA high phenotype of CD22 /[B6] B cells (Poe et al., 2004) (Fig. 5 F) , and CD22 /[B6] mice have a normal ratio of mature to immature/transitional peripheral B cells (Poe et al., 2004) . Thereby, elevated cell surface CD5 and HSA densities were phenotypic indicators for B cell AICD after BCR ligation.
was largely normalized in EndoU
EndoU-deficient Ig Tg sHEL mice produce auto-Abs A defining feature of Ig Tg sHEL mice is the paucity of anti-HEL auto-Ab production. To examine EndoU function in this process, EndoU / Ig Tg sHEL mice were generated. Serum anti-HEL auto-Ab levels were strikingly high in some EndoU / Ig Tg sHEL mice, which were labeled "high responders" (Fig. 6 A) . Anti-HEL auto-Ab levels in high-responder EndoU / Ig Tg sHEL mice were even greater than the levels of spontaneous anti-HEL Ab produced in Ig Tg mice (1.9-fold increase, P = 0.02) and EndoU / Ig Tg mice (1.8-fold increase, P < 0.01) lacking auto-Ag. High-responder EndoU / Ig Tg sHEL mice were present in both sexes, and carried both the Ig Tg and sHEL transgenes (Fig. 6 B) . High serum anti-HEL auto-Ab levels developed in most high-responder mice after 5 wk of age and were maximal by 9-12 wk of age (Fig. 6, A and C) . In addition to high-responder EndoU / Ig Tg sHEL mice, their age-matched littermates had augmented anti-HEL auto-Ab levels that were 2.4-fold higher than Ig Tg sHEL mice (P = 0.01, Fig. 6 A) . Anti-HEL auto-Ab levels in augmented-responder mice continued to increase with age (Fig. 6 D) , whereas anti-HEL auto-Abs were not enhanced in old Ig Tg sHEL mice (not depicted). Thus, EndoU overexpression regulates B cell autoAg responses in Ig Tg sHEL mice.
EndoU deficiency normalizes the phenotype of Ig Tg sHEL mice
Compared with Ig Tg sHEL mice, high-responder EndoU / Ig Tg sHEL mice had a marked increase in B cell blast in the presence of Mn 2+ , a condition favorable for XendoU endonuclease activity (Laneve et al., 2003) . Mn 2+ chelation did not interfere with EndoU binding of ssRNA molecules, as described for XendoU (Gioia et al., 2005) . Thus, EndoU binds ssRNAs, likely through its predicted XendoU Superfamily domain (see Fig. 8 A) .
Because c-Myc expression is reduced in CD22 /[B6] and Ig Tg sHEL B cells after BCR ligation and c-Myc transcripts contain numerous stretches of poly(U) residues within the 3 untranslated region (3-UTR, Fig. 3 F) , c-Myc mRNA interactions with EndoU were examined. Like the XendoU ssRNA substrate, c-Myc mRNA was also bound by recombinant EndoU (Fig. 3 F) , but mRNA cleavage was not detectable (not depicted). Thus, c-Myc mRNA is a potential EndoU substrate, which may explain reduced c-Myc expression when B cells overexpress EndoU. Further supporting this notion, ectopic EndoU expression in mouse NIH-3T3 fibroblasts significantly reduced c-Myc protein levels (Fig. 3 G; 32% decrease, P < 0.05).
EndoU deficiency reverses CD22 /[B6] B cell AICD
Because EndoU expression is low in WT and CD22 /[inbr] B cells after BCR ligation (Fig. 3, B and C) , the effect of reduced EndoU expression on CD22 /[B6] B cell AICD was assessed. EndoU-deficient mice were generated by appropriately targeting the EndoU gene on B6 Chr 15 (Fig. 4, A-C) . PCR-based SNP genotyping of genomic DNA from targeted mice confirmed that the targeted EndoU locus was B6 in origin. The chimeric mice were then bred onto a B6 genetic background to generate EndoU /[B6] mice that were homozygous B6:B6 throughout the 93.3-98.3 Mbp Chr 15 region (unpublished data). The absence of EndoU protein in homozygous gene-targeted mice was confirmed by Western blot analysis, which identified an appropriately sized protein in WT mice (Fig. 4 D) . EndoU from CD22 /[B6] B cells and thymocytes migrated more slowly on SDS-PAGE gels (50 kD band) than EndoU from CD22 /[inbr] thymocytes (48 kD band, Figs. 3 C and 4 E), due to a nonsynonymous SNP present within EndoU exon 2 which switches a single Glu (B6 mice) to Lys (129 mice). This was verified using A/J mice that share the EndoU SNP sequence with 129 mice, with EndoU from both CD22 / [inbr] and A/J mice migrating identically (Fig. 4 F) (Fig. 5 A) . AICD was also reversed in B cells from EndoU / CD22 /[B6] mice with normal BCR-induced blast development (Fig. 5 B) and proliferation (Fig. 5 C) . c-Myc expression was also normalized in BCR- (Fig. 5, D and E) . EndoU may preferentially regulate and high CD5 and HSA expression, with low spleen B cell numbers (Fig. 6, E and F) . The frequency of IgM a-high B cells in augmented-responder mice (11% ± 2.1%) was significantly greater than the frequency of IgM a-high B cells present in Ig Tg sHEL mice (2.2 ± 0.5%, P < 0.01). Thus, the normalized phenotype of high-responder EndoU / Ig Tg sHEL mice and the IgM a-low CD5 high HSA high phenotype of augmentedresponder EndoU / Ig Tg sHEL B cells suggests differential sensitivities to auto-Ag exposure.
Whether reduced B cell AICD led to the depletion of sHEL auto-Ag in EndoU / Ig Tg sHEL mice with age was examined. Blood B220 + cells isolated from Ig Tg and high-responder development and c-Myc expression after BCR ligation, increased spleen B cell numbers and surface IgM a expression, and reduced CD5 and HSA expression (Fig. 6, E and F) . In fact, high-responder mice were comparable to Ig Tg and EndoU / Ig Tg littermates lacking sHEL auto-Ag, except that surface IgM a levels were modestly decreased. In contrast, augmentedresponder EndoU / Ig Tg sHEL mice remained phenotypically similar to Ig Tg sHEL mice. Some B cells in augmentedresponder mice exhibited surface IgM a levels comparable to high-responder and Ig Tg B cells (Fig. 6 F, small 
DISCUSSION
EndoU was identified in a gene modifier screen as a unique and potent regulator of B cell AICD. In WT [B6] (Fig. 7 A) , suggesting that their BCRs were not occupied by sHEL. In contrast, B cells from both Ig Tg sHEL and augmented-responder EndoU / Ig Tg sHEL mice maintained an IgM a-low phenotype and did not bind labeled HEL protein, indicating BCR occupancy by sHEL. Dye-labeled spleen B cells from high-responder EndoU / Ig Tg sHEL mice were also adoptively transferred into WT or sHEL transgenic mice (Fig. 7 B) . There was a dramatic reduction in IgM levels and HEL-binding capacity for high-responder B cells recovered from sHEL recipients in comparison with WT recipients (Fig. 7, B and C) . Thus, the absence of AICD in high-responder EndoU / Ig Tg sHEL mice promoted auto-Ab production and endogenous sHEL clearance in vivo. EndoU 5 promoter region and 3-UTR between B6 mice and humans (Fig. 8 C) . mice. Genetic deletion of EndoU normalized this B cell phenotype in a substantial number of Ig Tg sHEL mice, which correlated with robust anti-HEL auto-Ab responses at an early age in mice that were defined as high responders. In augmented-responder EndoU / Ig Tg sHEL mice, some B cells expressed normalized phenotypes, suggesting that some B cells escape from an AICD phenotype with age to generate higher anti-HEL auto-Ab levels than Ig Tg sHEL mice. Given the linkage between EndoU, c-Myc up-regulation and AICD, it is likely that decreased B cell AICD in EndoU / Ig Tg sHEL mice leads to increased numbers of B cells that eventually consume endogenous sHEL auto-Ag, permitting clonal expansion with a resultant increase in anti-HEL auto-Ab production.
The divergence of phenotypes between high-responder and augmented-responder mice has precedent based on previous studies. For example, Ig Tg sHEL mice deficient in the inositol phosphatase PTEN have reduced BCR occupancy by sHEL and produce anti-HEL auto-Abs at a higher level than Ig Tg sHEL mice. This results in a subsequent break in tolerance in some mice caused by depletion of available sHEL auto-Ag (Browne et al., 2009) . Likewise, Ig Tg sHEL mice transgenic for CD19 overexpression progressively break tolerance as they age and eventually produce high anti-HEL autoAb levels (Inaoki et al., 1997) . In fact, remarkably similar to EndoU / Ig Tg sHEL mice, CD19 Tg Ig Tg sHEL mice develop as both high-and augmented-responder mice by 2 mo of age. Thus, modest increases in B cell numbers or enhancement in auto-Ab production resulting from altered B cell signaling can lead to auto-Ag depletion. Once this initial reduction in sHEL levels occurs, the resulting lack of B cell anergy enables peripheral B cell numbers to be maintained at a level that exceeds sHEL production, resulting in sustained and high-level anti-HEL auto-Ab production. Thereby, the EndoU regulatory pathway is likely to be an important component of B cell tolerance regulation, which is consistent with the known polygenic origins of autoimmunity.
The EndoU gene has an ancient origin, with conserved orthologs found in lower vertebrates (Suzuki et al., 2002; Gioia et al., 2005) and in invertebrates (Fig. 8, A and B) . up-regulation is uniquely impaired in CD22 /[B6] B cells (Poe et al., 2004) , c-Myc expression was normalized in CD22 /[B6] B cells by EndoU deficiency, EndoU bound c-Myc mRNA in vitro, and ectopic EndoU expression in a fibroblast cell line reduced c-Myc levels. A regulatory role for c-Myc in the mouse WEHI-231 B cell model of AICD has been previously described (Sonenshein, 1997; Donjerković and Scott, 2000) . In CD22 / mice, EndoU overexpression and AICD required B6 homozygosity at the EndoU locus. Therefore, genetic alterations must exist within the EndoU locus between the B6 and 129 genetic backgrounds that positively influences EndoU [B6] allele transcription in B cells, but not T cells. Although the EndoU locus has yet to be finemapped or sequenced in 129 mice, these important regulatory elements are likely to be located within the numerous stretches of conserved noncoding DNA present within the EndoU transcripts expressed in mouse B cells encoded a protein of 454 amino acids, which includes an N-terminal somatomedin B-like domain believed to be involved in protein-protein interactions (Gijsbers et al., 2003) , a XendoU Superfamily ssRNA-binding domain, and a predicted transmembrane domain. EndoU specifically interacted with an ssRNA substrate harboring U-rich sequences that is also bound by XendoU, which is implicated in small nucleolar RNA processing in Xenopus (Gioia et al., 2005; Renzi et al., 2006) . XendoU apparently generates snoRNAs through the cleavage of premRNAs encoded within introns (Laneve et al., 2003) . Human EndoU may exhibit low-level U-directed ssRNA endoribonuclease activity against the same in vitro ssRNA substrates recognized by XendoU (Laneve et al., 2008) . However, mouse EndoU did not demonstrate measurable endonuclease activity against XendoU substrates. Mammalian EndoU may thus be functionally distinct from its Xenopus ortholog because human EndoU is excluded from the nucleolus of multiple cell lines (http://www.proteinatlas.org/ENSG00000111405/subcellular).
Viral orthologs of EndoU also exist (Fig. 8 B) . Nsp15 (NendoU) is unique to the nidovirus family of ssRNA viruses, which includes the SARS coronavirus (Laneve et al., 2003; Bhardwaj et al., 2004; Ivanov et al., 2004; Gioia et al., 2005) . Although Nsp15 is required for viral replication, specific Nsp15 substrates have not been identified and, surprisingly, appear to exclude the viral genome itself (Ivanov et al., 2004) . Nsp15 has been postulated to suppress host immune responses (Ricagno et al., 2006) and to facilitate apoptosis in cells expressing the MAVS (mitochondrial anti-viral signaling) adapter protein that induces host anti-viral responses (Lei et al., 2009) . Mouse hepatitis virus is also a member of the nidovirus family, is lymphotropic, and induces immunosuppression at least in part through the elimination of developing B cells (Lamontagne et al., 1989; Jolicoeur and Lamontagne, 1994) . It therefore remains possible that mouse EndoU and hepatitis virus Nsp15 may target similar ssRNA substrates in B cells despite their evolutionary divergence. If true, each would have the capacity to suppress immune responses by inducing B cell AICD.
The current studies demonstrate for the first time that an RNA-binding protein plays a major role in regulating AICD, c-Myc expression, and the phenotype of peripheral B cells. Furthermore, these studies suggest an EndoU, CD22, c-Myc, and CD19 regulatory loop that directs normal B cell survival and malignant transformation (Fujimoto et al., 1999; Poe et al., 2012) . EndoU likely regulates c-Myc and potentially other crucial ssRNA (mRNA or pre-mRNA) transcripts and nonclassical ssRNAs that directly regulate or fine-tune specific subsets of genes required for optimal B cell proliferation and survival. For autoreactive B cells that survive central selection and inhabit peripheral tissues, EndoU overexpression has nonetheless evolved as a checkpoint protein within the complex pathway that keeps potentially pathogenic B cells at bay through deletion via AICD.
MATERIALS AND METHODS
Mice. All procedures were approved by the Duke University Institutional Animal Care and Use Committee. CD22 /[B6] and CD22 /[inbr] mice were as previously described (Poe et al., 2004) . EndoU / CD22 /[B6] mice were produced by breeding EndoU / mice with CD22 /[B6] mice, and then crossing heterozygous F1 animals to generate homozygous mice. WT littermates generated from the same F1 intercross served as controls. Ig Tg and Ig Tg sHEL mice (B6 background) were as previously described (Goodnow et al., 1989) , with the Ig Tg and sHEL transgenes confirmed using JAX Mice Genotyping Protocols (The Jackson Laboratory).
To disrupt the EndoU gene by homologous recombination, an 8 kb DNA fragment containing exons 1-7 was isolated from a B6 genomic BAC clone (RP24-169P4). Flanking BsmBI restriction sites were used to remove the distal end of exon 4, a portion of intron 4 and the splice donor site, which was replaced with a neomycin-resistance gene (neo r ) that introduced an inframe termination codon. A thymidine kinase (tk) gene was inserted at the 5 end of the EndoU targeting sequence. Appropriate homologous recombination in EF1 (B6:129 hybrid) embryonic stem cells (Duke Transgenic Mouse Facility) was confirmed by Southern blot analysis of HindIII digested genomic DNA using a probe outside of the targeting sequence. The targeted allele generated an expected 8.5 kb band, compared with the WT 7.5 kb fragment. Correct EndoU gene targeting in subsequent offspring was verified by PCR analysis using a common forward primer (PCR1) in combination with reverse primers either 3 of (PCR2) or within (PCR3) the inserted neo r gene.
B cell blast development and proliferation. Purified spleen B cells (B Cell isolation kit; Miltenyi Biotec) were analyzed by flow cytometry for blast development after 48 h of culture with F(ab) 2 goat anti-mouse IgM Abs as previously described (Poe et al., 2004) . Alternatively, B cell proliferation during 72-h cultures was assessed by 3 H-thymidine incorporation or CFSE labeling and dilution as previously described (Poe et al., 2004) .
Flow cytometry analysis. Assessment of cell surface Ags was performed by flow cytometry using fluorochrome-conjugated Abs as previously described (Poe et al., 2004) . For intracellular c-Myc and PCNA expression, purified spleen B cells were cultured for 18 h in the presence or absence of F(ab) 2 anti-mouse IgM Ab and then fixed and permeabilized using a Cytofix/ Cytoperm Plus kit (BD). Intracellular protein staining used either c-Myc Ab (IgG1 clone 9E10; BioLegend), followed by RPE-conjugated goat anti-mouse IgG1 secondary Abs (SouthernBiotech), or PCNA Ab (FITC-conjugated mouse IgG2a clone PC10; eBioscience). Immunofluorescence staining was assessed by flow cytometry, with background staining levels determined using nonreactive isotype-matched, fluorochrome-conjugated control Abs. Asterisks indicate conserved residues within similar functional groups. Numbers indicate the residue positions within mouse EndoU. The positions of the somatomedin B and XendoU domains are shown for reference. (B) Phylogenetic gene tree comparison of EndoU and its orthologs in eukaryotes, prokaryotes, and members of the coronaviruses. The neighbor-joining method was used to construct a phylogenetic tree using outgroup sequences for mouse endoribonucleases Ern1 and Dicer1. The outgroups were removed from the diagram for clarity. Bootstrap values from 1,000 replications are noted near branches. (C) Gene sequence homology between mouse and human EndoU. The region of mouse Chr 15 containing the entire EndoU locus was analyzed against the human genome using the VISTA Browser whole genome comparative analysis tool (http://genome.lbl.gov/vista/index.shtml), with a calculation window and minimum conservation width of 100 bp. Homologous regions of >50% identity are indicated by colored peaks, with predictions of exons, the 3-UTR, and conserved noncoding regions as indicated. For reference, the cartoon graphic above the bottom panel shows the actual positions of EndoU exons and the 3-UTR to scale.
For XendoU substrates, the reactions were performed for 45 min in the presence or absence of 5 mM Mn 2+ or 20 mM EDTA before analysis by 15% PAGE, with phosphorimager visualization. For c-Myc RNA, binding was assessed by scintillation counting.
To induce EndoU expression in mouse NIH-3T3 fibroblasts, cells were transfected (FuGENE HD; Promega) with a plasmid containing full length EndoU fused at the N terminus with CFP using the pECFP-N1 expression vector backbone (Takara Bio Inc.). Control-transfected reporter-positive NIH-3T3 cells were generated independently using the CFP (pECFP-N1) vector alone, or by co-transfection using the vector alone expressing GPF (pEGFP-C1), with similar results. Cells with stable plasmid incorporation were selected for appropriate reporter expression in the presence of 1 mg/ml Geneticin (Life Technologies).
ELISAs. Serum anti-HEL Ab levels in mice expressing the Ig Tg transgene were measured using serum diluted 1:100 in Tris-buffered saline containing 1% BSA as previously described (Inaoki et al., 1997) .
Fluorescent labeling of HEL protein for flow cytometry analysis.
Fluorescently labeled HEL protein (Sigma-Aldrich) was made using Pacific blue succinimidyl ester (Invitrogen) according to the manufacturer's instructions, and dialyzed 4× against a large volume of room temperature PBS.
Adoptive transfer experiments. Purified spleen B cells (15 × 10 6 ) from high-responder EndoU / Ig Tg sHEL mice were labeled with eFluor 670 cell tracking dye (eBioscience) and injected intraperitoneally in sterile PBS into WT or sHEL recipient mice. After 36 h, peritoneal cavity and spleen leukocytes were harvested and analyzed by flow cytometry for the presence of the adoptively transferred B cells along with assessment of their IgM a surface expression levels and HEL-binding capacity. Manly et al., 2001) . Informative SNPs between B6 and 129 mice were identified using the Mouse Genome Informatics and dbSNP databases. DNA primer pairs were used to PCR amplify these SNPs and their surrounding sequences, which were sequenced (Duke Cancer Center DNA Analysis Facility) to identify single nucleotide (homozygous B6:B6) or double nucleotide (heterozygous B6:129) peaks at SNP sites.
Gene expression analysis. Spleen B cells from mice of the indicated genotypes were cultured in triplicate for 18 h in medium alone or with F(ab) 2 anti-mouse IgM Ab, and then total RNA was isolated from pooled cells (RNeasy Plus; QIAGEN). For analysis of c-Myc and other signaling molecules, [ 32 P]-radiolabeled cDNA was generated and hybridized to GEArray NF-B signaling pathway gene arrays (SABiosciences) according to the manufacturer's instructions, with hybridization assessed using x-ray film. Gene expression within the Chr 15 locus was analyzed using Mouse 430.2 RNA arrays (Affymetrix; Duke Cancer Inst. DNA Analysis Facility) with GeneSpring GX software (Agilent Technologies) analysis. For real-time PCR analysis, cDNA was synthesized using random primers and analyzed using a LightCycler Instrument (software version 3) and FastStart DNA Master PLUS SYBR Green I kit (Roche Diagnostics Corp), with EndoU expression quantified using EndoU exon 5 (forward) 5-CGTCAACGAGAAGCTGTTCTCCAAG-3 and EndoU exon 6 (reverse) 5-CCACATGTTCTTCAAATCGTCCAC-3 primers. Cd20 expression was the internal control. Relative EndoU expression was quantified using the REST program (version 2).
Western blot analysis. Polyclonal antiserum reactive with EndoU was generated using purified recombinant EndoU protein (347 amino acids, 107-454) fused at the C terminus with a 6-His tag and produced in the BL21 strain of E. coli. EndoU protein was affinity-purified on His-agarose, yielding a single band of correct size on SDS-PAGE gels. Rabbits were immunized and boosted with EndoU protein in adjuvant (Maine Biotechnology Services, Inc.). Anti-EndoU Ab was affinity-purified from immune sera using recombinant EndoU protein covalently bound to agarose beads. Purified spleen B cells or CD4 + T cells (CD4 + T Cell isolation kit; Miltenyi Biotec) were cultured with F(ab) 2 anti-IgM Abs for B cells or CD3e mAb for T cells (16.7 µg/ml, clone 500A2; BD) for 18 h. 10 6 cell equivalents of detergent lysates were separated by SDS-PAGE, followed by transfer to nitrocellulose membranes, with EndoU detected using anti-EndoU Ab, HRP-conjugated donkey anti-rabbit IgG (H+L) secondary Ab (Jackson ImmunoResearch Laboratories), and a Pico Enhanced Chemiluminescence kit (Pierce). The blots were stripped and reprobed with a polyclonal ERK2 Ab (C-14; Santa Cruz Biotechnology, Inc.) to ensure equivalent sample loading. Thymocytes (1.5 × 10 6 cell equivalents/lane) were also analyzed, with the blots reprobed using either polyclonal ERK2 Ab or polyclonal Lck Ab (2102, Santa Cruz Biotechnology, Inc.).
EndoU binding to RNA substrates and transfection of NIH-3T3 cells. To assess EndoU binding activity, [ 32 P]-labeled ssRNA substrates for XendoU (Laneve et al., 2008) were generated in vitro using dsDNA template oligonucleotides with the SP6 promoter to drive transcription. Full-length [ 32 P]-labeled c-Myc mRNA was transcribed in vitro. Recombinant EndoU protein with a fused IgG binding domain tag was adsorbed onto MagnaBind goat IgG beads (Thermo Fisher Scientific), and incubated with substrate RNAs. Molar excess (100-fold) BSA and yeast tRNA were used as carriers.
